Fate Therapeutics Stock News

SAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will present at the following upcoming investor conferences:

SAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the develop

Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q4 2021 Results - Earnings Call Transcript

Fate Therapeutics press release (NASDAQ:FATE): Q4 GAAP EPS of -$0.72 misses by $0.04.Revenue of $17.07M (+7.4% Y/Y) beats by $5.52M.

Enrollment Ongoing in Multi-dose, Multi-cycle Escalation Cohort of FT596+R at 900 Million Cells per Dose for R/R BCL; Interim Phase 1 Data of 16 Patients Showed 69% ORR and 56% CR in Single-dose Escalation Cohorts of FT596+R at ≥90 Million Cells

Fate Therapeutics (FATE) delivered earnings and revenue surprises of -5.88% and 30.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Fate Therapeutics (NASDAQ:FATE) is scheduled to announce Q4 earnings results on Monday, Feb. 28, after market close.The consensus EPS estimate is -$0.66

SAN DIEGO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the develop

Natural-killer cell therapy is one of the most recent paradigms in cancer treatment, and two prominent companies working on this new technology are Fate Therapeutics Inc (NASDAQ: FATE ) and Century Therapeutics Inc (NASDAQ: IPSC ), an analyst at BofA Securities said in a note on Tuesday. The Biopharma Analyst: Tazeen Ahmad has a Buy rating and $112 price target on Fate shares. The analyst rates Century a Buy with a $34 price target. The Biopharma Thesis: Fate''s To-Date Progress Is Encouraging: Fate''s pipeline of NK assets are currently in the clinic for liquid tumors, Ahmad said in a note. These assets have shown robust response rates and a manageable safety profile, he added. A recent clinical update from the 2021 ASH conference vouches for the redosing potential of NK cells, the analyst said. The company plans to focus on moving their NK cell therapy into earlier lines, in combination with monoclonal Full story available on Benzinga.com

Natural-killer cell therapy is one of the most recent paradigms in cancer treatment, and two prominent companies working on this new technology are Fate Therapeutics Inc  FATE and Century Therapeuti

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.

In last trading session, Fate Therapeutics Inc. (NASDAQ:FATE) saw 0.8 million shares changing hands with its beta currently measuring 1.70. Company’s recent per share price level of $38.91 trading at $1.07 or 2.83% at ring of the bell on the day assigns it a market valuation of $3.63B. That closing price of FATE’s stock is … Fate Therapeutics Inc. (NASDAQ:FATE) Has Made The 13.9% Recovery, Could Gain Another -203.62% Ahead Read More »